SATERINONE

Details

Stereochemistry	RACEMIC
Molecular Formula	C27H30N4O4
Molecular Weight	474.5515
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(C=CC=C1)N2CCN(CC(O)COC3=CC=C(C=C3)C4=C(C)NC(=O)C(=C4)C#N)CC2

InChI

InChIKey=KLEKLDFUYOZELG-UHFFFAOYSA-N

InChI=1S/C27H30N4O4/c1-19-24(15-21(16-28)27(33)29-19)20-7-9-23(10-8-20)35-18-22(32)17-30-11-13-31(14-12-30)25-5-3-4-6-26(25)34-2/h3-10,15,22,32H,11-14,17-18H2,1-2H3,(H,29,33)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14559131 / https://www.ncbi.nlm.nih.gov/pubmed/11862296

Saterinone, a dual-action drug combines both alpha-1 blocking vasodilatory property and phosphodiesterase III (PDE III) inhibition--mediated inotropism. PDE III inhibitors are well established in the acute intravenous treatment of patients with decompensated chronic congestive heart failure. Saterinone was demonstrated to be a safe and potent drug on short-term application without major changes in myocardial oxygen consumption. Saterinone was studied in phase II trials in Germany for the treatment of heart failure. However, the development of this drug has been discontinued.

Approval Year

PubMed

Title	Date	PubMed
Pharmacokinetics and hemodynamic effects of the phosphodiesterase III inhibitor saterinone in patients with chronic heart failure.	2003 Oct	14559131

Sample Use Guides

In Vivo Use Guide

Saterinone was given by intravenous infusion for 24 hours at a rate of 1.5 microg/kg per min

Route of Administration: Intravenous

Name

Type

Language

SATERINONE

Official Name

English

saterinone [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744